Nejat ÖZGÜL, Mehmet Faruk KÖSE, Hüseyin Levent KESKİN, Ahmet Taner TURAN, Mustafa Alper KARALÖK, İşın ÜREYEN, Nurettin BORAN, Hakkı Gökhan TULUNAY

Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy - a retrospective evaluation

To evaluate the effectiveness of the addition of epirubicin to conventional chemotherapy as a first-line therapy for stage III–IV epithelial ovarian cancer. Materials and methods: A total of 132 patients who had undergone primary cytoreductive surgery between January 1998 and March 2003 were enrolled in the study. Twenty-four cases were excluded. Out of the remaining 108 subjects, 35 received epirubicin/paclitaxel/carboplatin (Group EPC) and 73 were treated with paclitaxel/platinum (cisplatin or carboplatin) (Group PC). Results: The median follow-up period was 66.5 months. The clinical complete response was 94% in the EPC group and 97% in the PC group. The recurrence rate in the first 6 months after treatment was significantly higher in the PC than the EPC group (47% vs. 23%, P = 0.018). Triplet chemotherapy was not found to improve 2- and 5-year disease-free survival (DFS) statistically. No significant difference in overall survival was observed between the 2 groups (80% vs. 83% at 2 years and 56% vs. 57% at 5 years for the PC and the EPC group, respectively). The main toxicity in both groups was hematological, and it was particularly severe in the EPC group. Conclusion: The addition of epirubicin to the standard treatment protocol yielded an improvement in the DFS rate that was not statistically significant and caused a tolerable increase in toxicity.

Anahtar Kelimeler:

Key words: Epithelial ovarian cancer, gynecological oncology, chemotherapy

Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy - a retrospective evaluation

Keywords:

Key words: Epithelial ovarian cancer, gynecological oncology, chemotherapy,

PDF

___

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26. 2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6.
Bookman MA, McGuire WP 3rd, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O’Dwyer P, Rowinsky E, Gallion HH, Ozols RF. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14: 1895–902.
Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 2003; 90: S8–15. 5. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000; 5: 26–35.
Micha JP, Goldstein BH, Mattison JA, Bader K, Graham C, Rettenmaier MA, Brown JV, Markman M. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol 2005; 96: 132–5.
Rose PG, Rodriguez M, Waggoner S, Greer BE, Horowitz IR, Fowler JM, McGuire WP. Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study. J Clin Oncol 2000; 18: 2957–62.
Coleman RL. Emerging role of topotecan in front-line treatment of carcinoma of the ovary. Oncologist 2002; 7 (Suppl. 5): 46–55.
Escobar PF, Markman M, Rose P, Zanotti K, Webster K, Belinson J. Phase 2 trial of carboplatin, paclitaxel and irinotecan in ovarian, fallopian tube and primary peritoneal cancers. Gynecol Oncol 2004; 92: 192–6.
du Bois A, Belau A, Wagner U, Pfisterer J, Schmalfeldt B, Richter B, Staehle A, Jackisch C, Lueck HJ, Schroeder W et al. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). Gynecol Oncol 2005; 96: 444–51.
Bertelsen K, Jakobsen A, Andersen JE, Ahrons S, Pedersen PH, Kiaer H, Arffmann E, Bichel P, Boestofte E, Strİyer I et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 1987; 28: 161–9.
The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991; 9: 1668–74.
Homesley HD, Harry DS, O’Toole RV, Hoogstraten B, Franklin EW, Cavanagh D, Nahhas WA, Smith JJ, Lovelace JV. Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. A multicenter trial. Am J Clin Oncol 1992; 15: 129–34.
Benedet JK, Bender H, Jones H 3rd, Ngan HYS, Pecorelli S; FIGO Committee on Gynecologic Oncology. Staging Classifications and Clinical Practice Guidelines of Gynaecologic Cancers. Amsterdam: Elsevier; 2000.
World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication, No: 148. Geneva: WHO; 1979
Pujade-Lauraine E, du Bois A, Goupil A, Rochon J, Möbus V, Weber B, Olbricht S, Nitz U, Warm M, Richter B. Epirubicin/ paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first line treatment of ovarian cancer FIGO stages IIB-IV. Results of a randomized AGO-GINECOGCIG Intergroup phase III trial. Int J Gynecol Cancer 2005; 15 (Suppl. 3): 222–3.
Romanini A, Tanganelli L, Carnino F, Fanucchi A, Lionetto R, Pastorino S, Cosio S, Gadducci A, Conte PF. First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients. Gynecol Oncol 2003; 89: 354–9.
Gebbia V, Di Marco P, Borsellino N, Gebbia N, Valerio MR, Fallica G, Tirrito ML, Valenza R, Citarrella P, Benedetti Panici P. Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study. Anticancer Drugs 2003; 14: 359–64.
Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H et al. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 2003; 13 (Suppl. 2): 172–7.
Vermorken JB, Kobierska A, Chevallier B, Zanaboni F, Pawinski A, Bolis G. A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group. Ann Oncol 2000; 11: 1035–40.
du Bois A, Lück HJ, Bauknecht T, Meier W, Richter B, Kuhn W, Quaas J, Pfisterer J. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. J Clin Oncol 1999; 17: 46–51.
Ray-Coquard I, Bachelot T, Guastalla JP, Levy E, Tigaud JD, Vincent P, Dramais D, Assouline D, Pujade-Lauraine E. Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens. Gynecol Oncol 2003; 88: 351–7.